Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fractyl HealthGUTS -2.91%10 Earnings per Share (Diluted) is $-1.10 as of Jun. 2026. GuruFocus rates GUTS with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,160 Biotechnology companies, Fractyl Health ranks worse than 91.81% on this metric.
Fractyl Health's EPS (Basic) for the
three
months ended in Jun. 2026 was $-0.16.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.10.
During the past 3 years, the average EPS without NRIGrowth Rate was -33.00% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -30.70% per year.
During the past 7 years, Fractyl Health's highest 3-Year average EPS without NRI Growth Rate was -14.80% per year. The lowest was -70.70% per year. And the median was -27.65% per year.
Fractyl Health (NAS:GUTS) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Fractyl Health Earnings per Share (Diluted) Related Terms
Fractyl Health Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Fractyl Health's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GUTS vs PYPD, PLYX, COYA: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Fractyl Health's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fractyl Health PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fractyl Health's PE Ratio distribution charts can be found below:
* The bar in red indicates where Fractyl Health's PE Ratio falls into.
Fractyl Health Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Fractyl Health's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.10
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-1.10 mean?
Fractyl Health (GUTS) has a Earnings per Share (Diluted) of $-1.10 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Fractyl Health and its competitors. According to the industry distribution chart, Fractyl Health ranks #1065 out of 1160 companies in the Biotechnology industry, placing it in the top 91.8%.
Is Fractyl Health's Earnings per Share (Diluted) too high?
Fractyl Health's current Earnings per Share (Diluted) is $-1.10. Based on the distribution chart, Fractyl Health ranks #1065 out of 1160 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Fractyl Health has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Fractyl Health's Earnings per Share (Diluted) compare to PYPD and PLYX?
According to the Biotechnology industry distribution chart, Fractyl Health ranks #1065 out of 1160 companies for Earnings per Share (Diluted). This places Fractyl Health in the lower half of its industry. The industry median Earnings per Share (Diluted) is 15.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 15.95, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Fractyl Health and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fractyl Health's current Earnings per Share (Diluted) is $-1.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fractyl Health stock overvalued right now?
Fractyl Health (GUTS) has a current Earnings per Share (Diluted) of $-1.10. The current Earnings per Share (Diluted) is $-1.10. Fractyl Health's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Fractyl Health (GUTS), the current Earnings per Share (Diluted) is $-1.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.
10GF Score
Get the complete analysis for GUTS
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GUTS has been successfully added to your 
